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Abstract
The aim of this study was to determine risk factors for adverse events (AE)-related treatment discontinuation and severe anemia
among patients with chronic hepatitis C virus (HCV) genotype 1 infection, treated with first-generation protease inhibitor
(PI)-based therapy. We included all patients who initiated treatment with PI-based therapy at a Brazilian university hospital between
November 2013 and December 2014. We prospectively collected data from medical records using standardized questionnaires
and used Epi Info 6.0 for analysis. Severe anemia was defined as hemoglobin p8.5 mg/dL. We included 203 patients: 132
treated with telaprevir (TVR) and 71 treated with boceprevir (BOC). AE-related treatment discontinuation rate was 19.2% and
anemia was the main reason (38.5%). Risk factors for treatment discontinuation were higher comorbidity index (OR=1.85,
CI=1.05–3.25) for BOC, and higher bilirubin count (OR=1.02, CI=1.01–1.04) and lower BMI (OR=0.98, CI=0.96–0.99) for TVR.
Severe anemia occurred in 35 (17.2%) patients. Risk factors for this outcome were lower estimated glomerular filtration rate
(eGFR; OR=0.95, CI=0.91–0.98) for patients treated with TVR, and higher comorbidity index (OR=2.21, CI=1.04–4.67)
and ribavirin dosage (OR=0.84, CI=0.72–0.99) for those treated with BOC. Fifty-five (57.3%) patients treated with TVR and
15 (27.3%) patients treated with BOC achieved sustained virological response (SVR). Among patients who received TVR and
interrupted treatment due to AE (n=19), only 26.3% (n=5) achieved SVR (P=0.003). Higher number of comorbidities, lower
eGFR and advanced liver disease are associated with severe anemia and early treatment cessation, which may compromise
SVR achievement.
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Introduction
Hepatitis C virus (HCV) infection is the leading cause
of chronic liver disease and a major public health problem
worldwide, affecting 1.1–2% of the global population
(1–3). The course of HCV infection and the fibrosis
progression rate varies extremely and is influenced by
host, viral, and environmental factors (3–6). Patients with
chronic HCV infection are at increased risk of developing
cirrhosis, hepatic decompensation, and hepatocellular
carcinoma (7). Proper and effective antiviral treatment is
associated with a reduction in portal hypertension, hepatic
decompensation, hepatocellular carcinoma, liver trans-
plantation, and liver-related mortality (3,4).
Since the discovery of the HCV in 1989, treatment
options have improved. Interferon alfa (IFN-a) was the first
therapeutic option, with sustained virologic response
(SVR) rates of 8–21% (8). Afterwards, therapy consisted
in IFN-a combined to ribavirin (RBV), which enhanced
SVR rates to 40%, and then pegylated IFN-a (PEG-IFN-a)
and RBV, with SVR rates of 42–52% (9–11). In 2010,
direct antiviral agents (DAA) became available; the first
DAA were the protease inhibitors (PI) telaprevir (TVR) and
boceprevir (BOC). These drugs are used in combination
with PEG-IFN-a and RBV. The SVR among naive patients
treated with triple therapy based on TVR or BOC are 75%
and 67–68%, respectively (12–16). More recently, new
DAA targeting protease, NS5A, and polymerase inhibitors
allowed IFN-free effective regimens, with SVR rates
above 90% (17,18).
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Adverse events (AE) are common in both IFN-a and
PEG-IFN-a-based regimens. First-generation PIs increase
the rates of certain AE such as anemia, pruritus, rash,
gastrointestinal effects, and dysgeusia. Observational
cohort studies outside the context of clinical trials
demonstrated that AE rates are higher and tolerability of
PI-regimens tend to be worse than reported in clinical
trials, particularly for patients with comorbidities and
cirrhosis (19,20). AE can lead to treatment discontinua-
tion, which may compromise SVR achievement (19–21).
Treatment discontinuation rates due to AE in patients
treated with RBV associated with IFN-a or PEG-IFN-a
were 10 and 12%, respectively (22,23). First-generation
PI-based treatment discontinuation rates due to AE
vary from 12 to 17% in clinical trials and from 12 to 29%
in observational cohorts (19–21). Real-life studies
demonstrate that anemia is the most frequent adverse
event responsible for PI-based treatment discontinuation
(20,21).
Despite of the effectiveness and safety of new DAA,
treatments involving these drugs are costly and are an
economic burden for many countries. In these settings,
first-generation PI-based triple therapy may be a treatment
option for certain patients. On the other hand, high rates of
serious AE leading to PI discontinuation remain an issue
that could compromise treatment outcome. The aim of
this study is to determine the risk factors for treatment
discontinuation due to AE and severe anemia in a cohort
of Brazilian patients treated with TVR- or BOC-based
therapy.
Material and Methods
Patient enrollment and data collection
We included all patients with HCV genotype 1 chronic
infection who started treatment with PEG-IFN-a, RBV, and
either TVR or BOC at Hospital de Clínicas, Universidade
Estadual de Campinas, from November 2013 through
December 2014. Treatment naive patients and patients
that previously failed to PEG-IFN-a plus RBV treatment
were included. We excluded patients with HIV infection,
detectable hepatitis B surface antigen, evidence of hepatic
decompensation (ascites, encephalopathy, Child-Pugh
B or C), and drug or alcohol abuse. This study was
approved by the Ethics Committee of the Universidade
Estadual de Campinas, and was conducted in accordance
with the Helsinki Declaration.
We collected patient data after every clinical evalua-
tion using standardized questionnaires that included
demographic and anthropometric information, medical
history, and data on HCV infection such as fibrosis hepatic
stage, HCV viral loads, HCV genotype, and previous HCV
treatment history. Chronic HCV infection was defined as
the presence of HCV antibody (Abott AxSYM Anti-HCV
3.0; Abbott Laboratories, Germany) and detectable serum
HCV RNA (Amplicor HCV 3, Roche Diagnostics Systems
Inc., USA). Presence of diabetes mellitus was determined
according to the American Diabetes Association criteria
(24). The severity of comorbidities was estimated using
Charlson comorbidity index (CCI) (25). Hepatic histo-
logical evaluation was graded and staged according to
Metavir scoring system (26). The diagnosis of cirrhosis
was made upon histological examination (Metavir stage
F4), or a combination of characteristics that included
clinical (history of ascites, encephalopathy or variceal
bleeding), laboratorial (association of thrombocytopenia,
hypoalbuminemia, hyperbilirubinemia, and prolonged pro-
thrombin time), and imaging studies (splenomegaly, portal
hypertension, and elastography compatible with Metavir
stage F4).
Treatment was proposed to patients following standard
practices and guidelines at the outpatient clinic, with-
out influence from the study team. Patients received
a combination of TVR or BOC, and PEG-IFN-a 2a (180 mg)
or 2b (1.5 mg/kg) and RBV (weight-adjusted dose).
We performed a 4-week lead-in with PEG-IFN-a and RBV
prior to BOC. Lead-in phase for TVR was optional. 1125 mg
of TVR was given twice a day, and 800 mg of BOC was
administered 3 times a day, following meals. Changes
in PEG-IFN-a and RBV dosages were documented and
PI dosage did not change during treatment.
Clinical evaluation and laboratory data tests were
performed at baseline and every 4 weeks during treatment
or more frequently, if needed. Serum biochemical and
hematological analysis included glucose, hemoglobin
(Hb), platelets, neutrophils, bilirubin, albumin, creatinine
and prothrombin time. Estimated glomerular filtration rate
(eGFR) was calculated by Modification of Diet in Renal
Disease formula (27). HCV viral loads were determined at
baseline and treatment weeks 4, 8, 12, 24 and at follow-up
12 weeks after the end of treatment (SVR-12) using
Amplicor HCV 3, Roche Diagnostics Systems Inc. We
documented all reported AE and any clinically significant
abnormalities throughout the treatment period that led to
therapy cessation.
Anemia was defined as mild if Hb was between 10.1
and 12.9 g/dL in males and 10.1 and 11.9 g/dL in females;
moderate, if Hb was between 8.6 and 10.0 g/dL, and
severe, if Hb p8.5 g/dL. Anemia management included
RBV dose reduction, use of erythropoiesis-stimulating
agents, such as erythropoietin (EPO), and transfusion
of packed red blood cell (PRBC). Information about
use, dosage and timing of initiation of each strategy was
recorded. Anemia management and discontinuation of PI
or triple therapy was based on the discretion of the
physicians attending each patient.
Statistical analysis
We performed statistical analysis using Epi Info,
version 3.5.4 (CDC, USA). Baseline continuous data
were reported as median, and categorical values as
frequencies and percentages. Univariate analyses were
Braz J Med Biol Res | doi: 10.1590/1414-431X20165300
Complications in first-generation PI-treatment 2/9
performed using chi-square, Fisher’s, and analysis of
variation or Mann-Whitney, as appropriate. A Po0.05 was
considered to be statistically significant. Variables with
Po0.2 were selected for a backward logistic regression
model to evaluate risk factors for severe anemia,
treatment discontinuation due to AE and SVR rates.
Results are reported as hazard ratios and 95% confidence
interval (CI).
Results
We included 203 patients treated with triple therapy
based on TVR or BOC. Table 1 shows patients’
characteristics. Among all patients, median age was
52 years, most were male (68.5%) and Caucasian (87.7%).
The majority of patients had experienced HCV-treatment
(77.3%) and 49.8% had cirrhosis. Liver biopsy was
performed in 187 patients; 16 patients had a combination
of clinical, laboratory and imaging findings that were
compatible with cirrhosis.
PI interruption due to AE
Overall, 39 (19.2%) of 203 patients had PI discon-
tinued due to AE, which occurred in 24 (18.1%) of 132
patients treated with TVR and in 15 (21.1%) of 71 treated
with BOC. Among patients treated with TVR, anemia was
the main reason for PI discontinuation, occurring in
10 (41.6%) of 24 patients, followed by rash in 7 (29.2%),
anorectal disorders in 4 (16.6%), cirrhosis decompensation
in 1 (4.1%), soft tissue infection in 1 (4.1%), and uncon-
trollable vomiting in 1 (4.1%). Among patients treated
with BOC, anemia was also the main reason that lead
to PI discontinuation, occurring in 5 (37.5%) of 15 patients,
followed by cirrhosis decompensation in 3 (20%), uncon-
trollable vomiting in 2 (13.3%), rash in 1 (6.6%), and
infection in 1 (6.6%). Three (20%) patients discontinued
BOC due to other reasons.
Table 2 shows univariate and multivariate analyses
results of factors associated with PI discontinuation due to
AE. Concerning patients treated with TVR, univariate
analysis demonstrated that higher age, higher CCI,
cirrhosis, higher bilirubin count, and lower platelet counts
were associated with PI interruption. Multivariate analysis
revealed that higher bilirubin count and lower BMI were
associated with TVR discontinuation. Among those
patients treated with BOC, univariate analysis showed
that female gender, lower albumin count, and higher
prothrombin international normalized ratio (INR) were
associated with PI discontinuation due to AE. Higher
CCI was associated with BOC discontinuation in multi-
variate analysis.
Anemia
Anemia occurred during treatment in 187 (92.1%)
patients and was classified as mild in 87 (42.9%),
moderate in 65 (32%), and severe in 35 (17.2%). Table 3
illustrates factors associated with severe anemia. Among
patients treated with TVR, older age, female gender,
Table 1. Baseline characteristics of hepatitis C infected patients treated with protease inhibitor telaprevir
and boceprevir in Campinas, Brazil (n=203).
Variable Total (n=203) Telaprevir (n=132) Boceprevir (n=71)
Demographics
Age (years) 52 (22–76) 51 (29–76) 53 (22–70)
BMI (kg/m2) 27.1 (16.9–44.0) 27.4 (16.9–37.7) 26.7 (18.1–44.0)
Male, n (%) 139 (68.5) 91 (68.9) 48 (67.6)
Race
Caucasian, n (%) 178 (87.7) 115 (87.1) 63 (88.7)
Black, n (%) 8 (3.9) 5 (3.8) 3 (4.2)
Others, n (%) 17 (8.4) 12 (9.1) 5 (7.1)
Medical history
Diabetes mellitus, n (%) 38 (18.7) 28 (21.2) 10 (14.1)
Charlson comorbidity index 4 (1–9) 4 (1–8) 4 (1–9)
HCV subgenotype
1a, n (%) 87 (42.8) 56 (42.4) 31 (43.7)
1b, n (%) 85 (41.9) 55 (41.7) 30 (42.2)
Unknown, n (%) 31 (15.3) 21 (15.9) 10 (14.1)
Stage of liver fibrosis
None or minimal fibrosis, n (%) 14 (6.9) 11 (8.4) 3 (4.2)
Portal fibrosis, n (%) 39 (19.2) 24 (18.2) 15 (21.1)
Data are reported as medians and ranges, unless otherwise indicated. BMI: body mass index;
HCV: hepatitis C virus.
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higher CCI, and diabetes mellitus were associated with
development of severe anemia. Lower eGFR was
associated with development of severe anemia in
univariate analysis and multivariate logistic regression.
Among patients treated with BOC, female gender, higher
BMI, higher CCI, lower baseline albumin, and lower Hb
count were associated with development of severe
anemia. Higher CCI and higher baseline RBV dosage
were associated with development of severe anemia at
multivariate logistic regression.
Figure 1 shows changes in Hb in patients who develop
or not severe anemia according to the two PI-based
treatments. Among patients treated with TVR, the median
time to achieve severe anemia was 8 weeks and the
median time to Hb nadir was 12 weeks. In patients treated
with BOC, median time to achieve severe anemia and
to Hb nadir was 12 weeks. Throughout treatment,
Hb remained significantly lower in patients who developed
severe anemia for both PI compared to patients who did
not develop severe anemia. Strategies used for anemia
management were RBV dose reduction [32 patients
(15.8%)], EPO [15 (7.4%)], combination of EPO and
RBV dose reduction [55 (27%)], EPO and PRBC transfu-
sion [2 (0.9%)], RBV dose reduction and PRBC
Table 2. Results of univariate and multivariate analyses of factors associated with protease inhibitor (PI) interruption due to adverse
events, in patients with hepatitis C infection (n=203).
PI interruption No PI interruption Univariate Multivariate
P OR 95%CI
Telaprevir n=24 n=108
Age (years) 57.5 (42–76) 51 (29–69) 0.0013 1.03 0.93–1.14
Male, n (%) 18 (75.0) 73 (67.6) 0.4781
Charlson comorbidity index 6 (1–8) 3.5 (1–8) o0.0001 1.92 0.98–3.75
Diabetes mellitus, n (%) 8 (33.3) 20 (18.5) 0.1083 0.74 0.16–3.44
BMI (kg/m2) 25.2 (16.9–35.0) 27.9 (17.3–37.7) 0.1100 0.98 0.96–0.99
Cirrhosis, n (%) 17 (70.8) 48 (44.4) 0.0193 0.65 0.07–5.89
Naive to HCV therapy, n (%) 4 (16.7) 24 (22.2) 0.7829
RBV/weight (mg/kg) 14.8 (13.1–17.6) 15.0 (11.1–20.8) 0.8624
Albumin (g/dL) 4.3 (3.5–5.2) 4.4 (3.4–5.1) 0.3356
Bilirubin (g/dL) 1.05 (0.45–1.75) 0.75 (0.22–2.26) 0.0131 1.02 1.01–1.04
INR 1.13 (0.90–1.46) 1.01 (0.58–2.58) 0.0597 0.98 0.93–1.04
eGFR (MDRD) 89 (47–120) 95.5 (51–144) 0.2039
Hemoglobin (g/dL) 15.0 (10.7–16.9) 15.3 (11.4–18.7) 0.2255
Neutrophils (103/mm3) 2.69 (1.32–5.89) 3.18 (0.84–7.12) 0.0781 0.99 0.99–1.00
Platelets (109/L) 104.5 (55–396) 169.5 (50–400) 0.0055 1.00 1.00
Boceprevir n=15 n=56
Age (years) 54 (41–66) 53 (22–70) 0.5193
Male, n (%) 6 (40) 42 (75) 0.0146 0.22 0.03–1.71
Charlson comorbidity index 5 (2–8) 4 (1–9) 0.0534 1.85 1.05–3.25
Diabetes mellitus, n (%) 4 (26.7) 6 (10.7) 0.2023
BMI (kg/m2) 26.3 (19.8–38.9) 26.8 (18.1–44.0) 0.8887
Cirrhosis, n (%) 10 (66.7) 26 (46.4) 0.1638 0.22 0.02–2.18
Naive to HCV therapy, n (%) 6 (40.0) 12 (21.4) 0.1836 2.26 0.38–13.43
RBV/weight (mg/kg) 14.6 (12.7–17.0) 14.8 (12.5–18.3) 0.5062
Albumin (g/dL) 3.9 (3.3–4.8) 4.4 (3.3–5.2) 0.0020 0.93 0.74–1.15
Bilirubin (g/dL) 0.93 (0.51–2.11) 0.80 (0.18–3.51) 0.4810
INR 1.21 (0.99–1.59) 1.08 (0.91–1.46) 0.0185 1.06 0.99–1.3
eGFR (MDRD) 89 (42–122) 88.5 (54–123) 0.8271
Hemoglobin (g/dL) 14.4 (10.6–17.30) 15.4 (9.6–19.4) 0.0509 1.01 0.95–1.07
Neutrophils (103/mm3) 2.61 (1.50–5.08) 3.28 (0.87–7.12) 0.1015 0.99 0.99–1.00
Platelets (109/L) 107 (60–209) 156 (952–365) 0.0247 1.00 1.00
Data are reported as medians and ranges, unless otherwise indicated. Variables selected for the multivariate adjusted logistic regression
models are specified in bold in the univariate P column. OR: odds ratio; CI: confidence interval; BMI: body mass index; HCV: hepatitis C
virus; RBV: ribavirin; INR: prothrombin international normalize ratio; eGFR: glomerular renal function; MDRD: modification of diet in renal
disease.
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transfusion [3 (1.5%)] and the three strategies combined
[29 (14.2%)]. Median time for first introduction of any
anemia treatment was 8 weeks.
Sustained virological response
During the follow-up period, SVR-12 was available
for 151 patients. Among these patients, median age was
51 years; most were male (70.4%), and Caucasian (88.7%).
The majority of patients were HCV-treatment-experienced
(74.8%) and 49.7% had cirrhosis. Ninety-six (63.6%)
received TVR-based therapy and 55 (36.4%) received
BOC.
SVR-12 rates were 57.3% (55) in the TVR group and
27.3% (15) in the BOC group. Among patients treated with
TVR, SVR rates in 22 previously untreated, 36 relapsers,
and 25 non-responders were 81.8, 66.7 and 56.2%,
respectively. SVR rates for the subgenotypes were 54.8%
(42) for 1a, 56.4% (39) for 1b, and 15 patients were not
subgenotyped. Considering fibrosis stage, SVR rate was
100% (9) for minimum fibrosis, 73.3% (15) for portal fibrosis,
55% (20) for bridging fibrosis, and 46% (50) for cirrhosis. In
patients treated with BOC, SVR rates in 15 previously
untreated patients, 17 relapsers, and 18 non-responders
were 46.6, 41.2, and 5.5%, respectively. Regarding the
subgenotype, SVR rate was 25% (24) for 1a, 26.1% (17)
for 1b, and 21.4% (15) for non-subgenotyped patients.
Considering the fibrosis stage, SVR rate was 33.3% (3) for
minimum fibrosis, 63.6% (11) for portal fibrosis, 28.6% (14)
for bridging fibrosis, and 11.5% (26) for cirrhosis. Table 4
shows factors associated with SVR-12.
Table 3. Results of univariate and multivariate analyses of factors associated with severe anemia in a logistic regression model, in
patients with hepatitis C infection (n=203).
Severe anemia No severe anemia Univariate Multivariate
P OR 95%CI
Telaprevir n=24 n=108
Age (years) 62 (43–70) 51 (29–76) o0.0001 1.06 0.97–1.16
Male, n (%) 16 (66.7) 75 (69.4) 0.0467 1.45 0.38–5.56
Charlson comorbidity index 5 (2–8) 3 (1–8) 0.0003 1.01 0.59–1.70
Diabetes mellitus, n (%) 10 (41.7) 18 (16.7) 0.0067 3.53 0.90–13.68
BMI (kg/m2) 28.7 (16.9–37.5) 27.4 (17.3–37.7) 0.6777
Cirrhosis, n (%) 15 (62.5) 50 (46.3) 0.1509 1.54 0.37–6.38
Naive to HCV therapy, n (%) 5 (20.8) 23 (21.3) 0.9599
RBV/weight (mg/kg) 15.1 (11.1–17.3) 14.9 (11.4–20.8) 0.7628
Albumin (g/dL) 4.2 (3.9–5.2) 4.1 (3.4–5.1) 0.9409
Bilirubin (g/dL) 0.89 (0.33–2.22) 0.76 (0.22–2.26) 0.3068
INR 1.02 (0.91–1.28) 1.04 (0.58–2.58) 0.7322
eGFR (MDRD) 80.5 (47–112) 96 (66–144) 0.0001 0.95 0.91–0.98
Hemoglobin (g/dL) 14.9 (10.7–17.5) 15.3 (11.4–18.7) 0.0618 0.98 0.94–1.02
Platelets (109/L) 124 (57–396) 162 (50–400) 0.2682
Boceprevir n=12 n=59
Age, years 55 (41–68) 53 (22–70) 0.8962
Male, n (%) 2 (16.7) 46 (78.0) 0.0001 0.02 0.01–1.23
Charlson comorbidity index 5 (2–9) 4 (1–8) 0.0182 2.21 1.04–4.67
Diabetes mellitus, n (%) 3 (25.0) 7 (11.9) 0.3565
BMI (kg/m2) 31.2 (19.8–43.3) 26.6 (18.1–44.0) 0.0278 0.98 0.96–1.01
Cirrhosis, n (%) 8 (66.7) 28 (47.5) 0.3434
Naive to HCV therapy 5 (41.7) 13 (22.0) 0.1655 4.94 0.30–81.36
RBV/weight (mg/kg) 14.2 (12.7–16.3) 14.8 (12.5–18.3) 0.1953 0.84 0.72–0.99
Albumin (g/dL) 3.8 (3.3–4.8) 4.3 (3.3–5.2) 0.0079 0.98 0.76–1.25
Bilirubin (g/dL) 0.68 (0.51–3.51) 0.81 (0.18–3.21) 0.9379
INR 1.07 (0.95–1.34) 1.09 (0.91–1.59) 0.8537
eGFR (MDRD) 73 (42–122) 89 (55–123) 0.3074
Hemoglobin (g/dL) 13.5 (9.6–17.3) 15.4 (11.8–19.4) 0.0002 0.95 0.86–1.05
Platelets (109/L) 131 (65–361) 154 (52–365) 0.2254
Data are reported as medians and ranges, unless otherwise indicated. Variables selected for the multivariate adjusted logistic regression
models are specified in bold in the univariate P column. OR: odds ratio; CI: confidence interval; BMI: body mass index; HCV: hepatitis C
virus; RBV: ribavirin; INR: prothrombin international normalize ratio; eGFR: glomerular renal function; MDRD: modification of diet in renal
disease.
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In the TVR group, univariate analysis showed that
lower comorbidity index, no previous treatment, absence
of cirrhosis, lower bilirubin, lower INR, higher Hb, and
higher platelets counts at baseline were associated with
higher SVR-12. Multivariate analysis revealed that no pre-
treatment and lower INR at baseline were associated with
higher SVR-12. Among patients who interrupted treatment
due AE (19), only 5 (26.3%) achieved SVR (P=0.003).
Among patients treated with BOC, absence of cirrhosis
was associated with higher SVR-12 in univariate analysis.
Multivariate logistic regression demonstrated that lower
eGFR at baseline was associated to higher SVR 12. Only
23% (2) of patients who interrupted therapy due to AE (12)
reached SVR (P=0.477).
Discussion
Our study investigated AE in an observational cohort
of HCV infected patients and found that PI interruption due
to AE occurred in 19.2% of patients. Treatment interrup-
tion was associated with higher comorbidity index, lower
BMI, and advanced liver disease. Seventeen percent of
patients had severe anemia, which was the main reason
for PI discontinuation. Lower eGFR, no prior history for
HCV treatment and absence of cirrhosis was associated
with higher chances of SVR.
Treatment discontinuation due to AE was higher in
our study (19.2%) than in clinical trials for TVR and
BOC (10–13 and 8–12%, respectively) which could be
explained by the higher proportion of patients with cirrhosis
in our study (12–16). However, our AE-related treatment
discontinuation rate was similar to the CUPIC cohort (21%),
where anemia was also the main reason for PI discontinua-
tion (21). Risk factors for AE-related treatment discontinua-
tion were also consistent with other real-life cohorts,
showing that patients with higher number of comorbidities
and advanced liver disease are a difficult-to-treat popula-
tion with higher chances of treatment interruption due to AE
(19,21,28,29). Among patients treated with TVR, advanced
age and lower BMI was also a risk factor for treatment
interruption due to AE (29). Since TVR has fixed dose,
patients with lower body mass may have higher drug serum
concentration, which may induce more severe AE. Female
gender was associated with BOC-based treatment dis-
continuation due to AE in univariate analysis. However,
these data were not corroborated by other cohorts and
need further investigation.
Severe anemia rates in our sample was slightly lower
(17.2%) than in other reports (22.9–38%) (21,30,31).
This could be explained by our definition for severe
anemia, which was considered when Hb counts were
lower (p8.5 g/dL) than established by other authors
(p8.9 and p10.0 g/dL) (30,31). Predicting factors for the
development of severe anemia in multivariate logistic
regression were lower eGFR for patients who received
TVR, and higher CCI, and baseline RBV dosage for those
treated with BOC. We also found that older age and
presence of diabetes was associated with severe anemia
among patients treated with TVR in univariate analysis,
which is comparable to a previous observational cohort
(31). Since renal clearance is the major mechanism for
clearance of RBV, lower eGFR could lead to higher serum
levels of RBV, which is associated with lower Hb levels
(32). Presence of multiple comorbidities enhances the
chances of multifactorial anemia, possibly contributing to
the development of anemia in HCV-infected patients
treated with first-generation PI-based regimens (33).
These data suggest that patients with renal impairment,
older age, and multiple comorbidities should have closer
monitoring and early management for anemia to avoid
complications such as treatment discontinuation and
worsening of clinical status.
Several strategies for the management of anemia in
patients receiving triple therapy based on first-generation
PI exist. Since PI dosage cannot be reduced due to the
risk of resistance development, RBV dose reduction is the
main strategy used in the management of anemia in these
patients. TVR registration trials prohibited the use of EPO
for anemia management, although often experts recom-
mend initiating EPO when Hb levels persist lower than
10 g/dL despite RBV dose reductions. Red blood
cell transfusion is an option in the absence of response
Figure 1. Mean hemoglobin in patients treated for chronic
hepatitis C with telaprevir (A; n=132) and boceprevir (B, n=71).
Data are reported as mean±SD.
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to other measures or in the presence of clinical symptoms
(12,33). The main strategy used in our study was RBV
dose reduction associated with EPO, followed by RBV
dose reduction alone and the association of the three
strategies. Our rate of PRBC transfusion (34%) was
slightly lower than reported in previous studies (40–48%),
probably because we used it as the last option in order to
avoid transfusion-related complications (21,31). Our data
show a trend for severe anemia development in patients
with Hb p10.0 g/dL at week 4 as illustrated in Figure 1.
Median interval for initiation of treatment for anemia
corresponded to the median time to achieve Hb p8.5 g/L
(8 weeks), suggesting that early management is important
to avoid development of severe anemia.
Overall SVR rate for TVR-treated patients in our study
was 57.3%, which is comparable to other observational
cohorts (52–60.8%) (34,35). A cohort with 208 treatment
naive patients receiving TVR or BOC showed SVR rates
of 42% [36)]. Other real-life studies showed SVR rates
around 50% (21,28,35). However, the SVR rate for
patients treated with BOC in our study (27.3%) was
higher than in these studies. The high proportion of
Table 4. Results of univariate and multivariate analyses of factors associated with sustained virological response (SVR) in patients with
hepatitis C infection (n=151).
SVR No SVR Univariate Multivariate
P OR 95%CI
Telaprevir n=55 n=41
Age (years) 51 (33–76) 54 (29–64) 0.5100
Male, n (%) 41 (74.5) 28 (68.3) 0.5002
Charlson comorbidity index 3 (1–8) 4 (1–8) 0.0174 0.90 0.62–1.32
Diabetes mellitus, n (%) 8 (14.5) 13 (31.7) 0.0506 0.70 0.16–3.03
BMI (kg/m2) 27.1 (18.5–37.5) 27.2 (16.9–37.7) 0.9752
Cirrhosis, n (%) 23 (41.8) 27 (65.9) 0.0197 18.42 0.48–7.03
Naive to HCV therapy, n (%) 18 (32.7) 4 (9.8) 0.0129 5.29 1.34–20.87
RBV/weight (mg/kg) 14.9 (11.1–20.8) 15.0 (11.5–17.6) 0.5528
Albumin (g/dL) 4.4 (3.6–5.0) 4.3 (3.4–5.2) 0.5917
Bilirubin (g/dL) 0.75 (0.30–2.22) 0.88 (0.34–2.26) 0.0484 1.01 0.99–1.02
INR 1.00 (0.58–1.26) 1.11 (0.94–1.35) o0.001 0.90 0.84–0.96
eGFR (MDRD) 94 (51–144) 94 (47–142) 0.8055
Hemoglobin (g/dL) 15.3 (12.0–18.7) 15.1 (10.7–15.7) 0.0496 1.02 0.98–1.06
Neutrophils (103/mm3) 3110 (1390–7120) 2710 (840–6740) 0.2327
Platelets (109/L) 169 (62–388) 131 (50–396) 0.0485 1.00 1.00–1.00
HCV RNA (103 UI/mL) 844 (201–9440) 848 (104–4905) 0.8163
Boceprevir n=15 n=40
Age (years) 54 (34–66) 52 (27–70) 0.4722
Male, n (%) 11 (73.3) 27 (67.5) 0.7542
Charlson comorbidity Index 3 (1–7) 4 (1–8) 0.1328 0.80 0.37–1.71
Diabetes, n (%) 2 (13.3) 5 (12.5) 1.0000
BMI (kg/m2) 25.4 (23.6–43.3) 27.0 (18.1–38.9) 0.9526
Cirrhosis, n (%) 3 (20.0) 23 (57.5) 0.0167 0.60 0.03–9.35
Naive to HCV therapy, n (%) 7 (46.7) 8 (20.0) 0.0861 9.96 0.88–1.12
RBV/weight (mg/kg) 15.8 (13.5–17.1) 14.6 (12.8–17.8) 0.0852 1.06 0.98–1.14
Albumin (g/dL) 4.6 (3.9–4.8) 4.2 (3.3–5.2) 0.0539 1.14 0.80–1.61
Bilirubin (g/dL) 0.68 (0.42–2.31) 0.90 (0.35–3.51) 0.1720 1.00 0.97–1.02
INR 1.02 (0.97–1.41) 1.11 (0.93–1.59) 0.0650 0.95 0.86–1.05
eGFR (MDRD) 82 (50–104) 90 (54–122) 0.0707 0.92 0.85–0.99
Hemoglobin (g/dL) 15.0 (9.6–16.9) 15.2 (10.6–18.5) 0.3110
Neutrophils (103/mm3) 3450 (2120–7120) 3125 (870–6860) 0.1388 1.00 0.99–1.00
Platelets (109/L) 186 (52–361) 139 (58–365) 0.0682 1.00 1.00–1.00
HCV RNA (103 UI/mL) 292 (5–3876) 726 (25–6895) 0.2971
Data are reported as medians and ranges, unless otherwise indicated. Variables selected for the multivariate adjusted logistic regression
models are specified in bold in the univariate P column. OR: odds ratio; CI: confidence interval; BMI: body mass index; HCV: hepatitis C
virus; RBV: ribavirin; INR: prothrombin international normalize ratio; eGFR: glomerular renal function; MDRD: modification of diet in renal
disease.
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patients considered difficult to treat (74.7% of prior non-
responders, 75% of advanced fibrosis, and high number
of comorbidities), and the relatively small number of
patients in this group could explain these results. Two
observational cohorts demonstrated that cirrhosis and
prior treatment for HCV was associated with lack of SVR
(28,35). Likewise, multivariate analysis in our cohort
demonstrated that treatment-naive and lower baseline
INR patients treated with TVR had higher chances of
SVR. Among patients treated with BOC, lower eGFR was
associated with SVR. This could be explained by the fact
that lower eGFR could decrease drug clearance, exposing
patients to higher doses. Lastly, treatment interruption due
to AE was associated with lower chances of achieving
SVR among TVR-treated patients, highlighting the impor-
tance of predicting serious AE in order to allow more
timely interventions, potentially reducing the risk of
treatment cessation and poor outcome.
Limitations of our study include the population hetero-
geneity and the relatively small number of patients treated
with BOC. We also included patients treated at a single
tertiary care outpatient clinic. Since it was an observa-
tional study, PI group and strategies used in the manage-
ment of anemia could not be compared in terms of
outcomes. The strength of our study is its focus on
patients treated with DAA outside clinical registration
trials. To our knowledge, this is the first study to evaluate
predicting factors related to severe anemia and treatment
discontinuation in Brazil. We demonstrated the relation-
ship between lower eGFR, development of severe anemia
and higher chances of SVR.
We believe that it is important to investigate AE and
PI interruption rates to evaluate the limitations of first-
generation PI-based treatment, and to consider the need
for new DAA access. Furthermore, in many countries,
new DAA are not extensively available and first-genera-
tion PIs are accessible primarily to advanced fibrosis
patients. Our findings support that this strategy may
expose patients to higher rates of severe anemia,
treatment discontinuation and lower SVR rates. In this
setting, while new DAA are not universally available,
specific cases of previously untreated young patients,
with low fibrosis and comorbidity scores could possibly
benefit from treatment with triple therapy that are still
PEG-IFN-a/RBV based.
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